Ankylosing Spondylitis, COVID-19, Psoriatic Arthritis, Rheumatoid Arthritis, SARS-CoV Infection, Spondyloarthritis
Conditions
Keywords
COVID-19, SARS-COV-2 infection, Rheumatoid arthritis, Spondyloarthritis
Brief summary
The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing
Detailed description
The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Some treatments for chronic inflammatory rheumatisms such as TNF inibitors appear to have a protective effect against severe forms of COVID-19, while corticosteroids or other immunosuppressants may be associated with a higher prevalence of severe forms of COVID-19. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of out and inpatients with chronic inflammatory rheumatism (i.e. rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis) by serological testing and to compare prevalence according to type of chronic inflammatory rheumatism, DMARD class and symptomatic treatment (corticosteroid therapy, NSAIDs).
Interventions
None listed
Sponsors
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Patient with chronic inflammatory rheumatic disease (i.e. rheumatoid arthritis, psoriatic rheumatism, axial spondyloarthritis), Coming for consultation or hospitalization as part of the usual follow-up of his condition
Exclusion criteria
\- Adult patient under legal protection (guardianship, curatorship)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis | 1 day | Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments. | 1 day | Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments. |
| Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease | 1 day | Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease |
| Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics | 1 day | Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics |
Countries
France
Outcome results
None listed